-
1.发明申请Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications 有权具有人类主要组织相容性复合体（MHC）表型的转基因小鼠，实验用途和应用公开(公告)号：US20050114910A1
公开(公告)日：2005-05-26
申请号：US10882241
申请日：2004-07-02
IPC分类号： A01K67/027 , A61K49/00 , C07K14/74 , C12N15/85 , C12N5/06
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/70539 , C12N15/8509
摘要： The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
摘要翻译： 本发明涉及转基因小鼠和分离的转基因小鼠细胞，小鼠和小鼠细胞包含破坏的H 2类I基因，破坏的H 2类II基因，功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞对于H2类I和II类分子都是缺陷的，其中转基因小鼠包含功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞具有HLA-A2 + HLA-DR1 +β2m°IAbeta基因型。 本发明还涉及使用本发明的转基因小鼠的方法。
-
2.发明申请TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS 审中-公开具有人类重要组氨酸复合物（MHC）的转基因小鼠，实验用途和应用公开(公告)号：US20110142862A1
公开(公告)日：2011-06-16
申请号：US10566386
申请日：2004-07-05
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/70539 , C12N15/8509
摘要： The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
摘要翻译： 本发明涉及转基因小鼠和分离的转基因小鼠细胞，小鼠和小鼠细胞包含破坏的H 2类I基因，破坏的H 2类II基因，功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞对于H2类I和II类分子都是缺陷的，其中转基因小鼠包含功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞具有基因型HLA-A2 + HLA-DR1 +＆bgr; 2m°IA＆bgr;°。 本发明还涉及使用本发明的转基因小鼠的方法。
-
3.发明授权Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications 有权具有人类主要组织相容性复合体（MHC）表型的转基因小鼠，实验用途和应用公开(公告)号：US07663017B2
公开(公告)日：2010-02-16
申请号：US10882241
申请日：2004-07-02
IPC分类号： A01K67/00 , A01K67/033 , A01K67/027 , C12N15/00 , C12N5/00 , C12N5/10 , C12N15/63
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/70539 , C12N15/8509
摘要： The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
摘要翻译： 本发明涉及转基因小鼠和分离的转基因小鼠细胞，小鼠和小鼠细胞包含破坏的H 2类I基因，破坏的H 2类II基因，功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞对于H2类I和II类分子都是缺陷的，其中转基因小鼠包含功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞具有HLA-A2 + HLA-DR1 +β2m°IAbeta基因型。 本发明还涉及使用本发明的转基因小鼠的方法。
-
4.发明申请Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications 审中-公开具有人类主要组织相容性复合体（MHC）表型的转基因小鼠，实验用途和应用公开(公告)号：US20110067121A1
公开(公告)日：2011-03-17
申请号：US12654524
申请日：2009-12-22
IPC分类号： G01N33/15 , C07K14/00 , A01K67/027 , C07H21/02 , C07H21/04 , C12N5/10 , A61K39/00 , C12Q1/02 , A61P37/04
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/70539 , C12N15/8509
摘要： The present invention-relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
摘要翻译： 本发明涉及转基因小鼠和分离的转基因小鼠细胞，小鼠和小鼠细胞包含破坏的H 2类I基因，破坏的H 2类II基因，功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞对于H2类I和II类分子都是缺陷的，其中转基因小鼠包含功能性HLA I类转基因和功能性HLA II类转基因。 在实施方案中，转基因小鼠或小鼠细胞具有基因型HLA-A2 + HLA-DR1 +＆bgr; 2m°IA＆bgr;°。 本发明还涉及使用本发明的转基因小鼠的方法。
-
公开(公告)号：US09986721B2
公开(公告)日：2018-06-05
申请号：US13551137
申请日：2012-07-17
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/70539 , C12N15/8509
摘要： The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
-
公开(公告)号：US20170079253A1
公开(公告)日：2017-03-23
申请号：US13551137
申请日：2012-07-17
IPC分类号： A01K67/027 , A61K49/00 , C07K14/74
CPC分类号： A01K67/0278 , A01K67/0275 , A01K67/0276 , A01K2207/15 , A01K2217/00 , A01K2217/05 , A01K2217/052 , A01K2217/054 , A01K2217/075 , A01K2227/105 , A01K2267/03 , A61K49/0008 , C07K14/70539 , C12N15/8509
摘要： The present invention relates to transgenic mice and isolated transgenic mouse cells, the mice and mouse cells comprising a disrupted H2 class I gene, a disrupted H2 class II gene, a functional HLA class I transgene, and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cells are deficient for both H2 class I and class II molecules, wherein the transgenic mouse comprises a functional HLA class I transgene and a functional HLA class II transgene. In embodiments, the transgenic mouse or mouse cell has the genotype HLA-A2+HLA-DR1+β2m°IAβ°. The invention also relates to methods of using a transgenic mouse of the invention.
-
7.发明申请T CD4+ Epitopes of Type I and II Latency Antigens of the Epstein-Barr Virus, Which Can Be Recognized by the majority of individuals in the caucasian populations and applications thereof 审中-公开T型CD4 + Epstein-Barr病毒的I型和II型潜伏性抗原表位，其可被白种人群中大多数个体识别及其应用公开(公告)号：US20090130134A1
公开(公告)日：2009-05-21
申请号：US11883814
申请日：2006-02-02
申请人： Veronique Pancre , Claude Auriault , Stephane Depil , Bernard Maillere , Olivier Morales , Gaetan Munier
发明人： Veronique Pancre , Claude Auriault , Stephane Depil , Bernard Maillere , Olivier Morales , Gaetan Munier
CPC分类号： C07K14/005 , C12N2710/16222 , C12N2710/16622
摘要： The invention relates to immunogenic peptides from EBV type I and II latency antigens, comprising at least one T CD4+ epitope which can be recognized by the majority of individuals in the Caucasian population. The invention also relates to the diagnostic and therapeutic applications of same.
摘要翻译： 本发明涉及来自EBV I型和II型潜伏期抗原的免疫原性肽，其包含至少一种可被白种人群体中大多数个体识别的T CD4 +表位。 本发明还涉及其相关的诊断和治疗应用。
-
公开(公告)号：US5071959A
公开(公告)日：1991-12-10
申请号：US168009
申请日：1988-03-01
申请人： Andre Capron , Michel Joseph , Veronique Pancre , Claude Auriault
发明人： Andre Capron , Michel Joseph , Veronique Pancre , Claude Auriault
IPC分类号： C12P21/00 , A61K38/00 , A61P37/00 , A61P37/08 , C07K1/20 , C07K14/005 , C07K14/195 , C07K14/52 , C12R1/91
摘要： New lymphokine and its isolation and purification process. Said lymphokine is comprised of a factor obtained from T cells stimulated by concanavaline A or by an antigen capable of inhibiting the IgE-dependent platelet citotoxicity with respect to young larvae of S. Mansoni, of strongly reducing the chemiluminescence of blood platelets in a reaction IgE-anti-IgE, which is a correlate of the anti-parasite cytotoxicity, and of inhibiting the platelet activation in non-IgE dependent intolerences. Application as suppressor agent for suppressing platelet activation and as immunomodulator medicament of allergies.
摘要翻译： PCT No.PCT / FR87 / 00164 Sec。 371日期1988年3月1日 102（e）1988年3月1日PCT提交1987年5月19日PCT公布。 公开号WO87 / 07303 1987年12月3日。新淋巴因子及其分离纯化过程。 所述淋巴因子包括由苦参碱A刺激的T细胞获得的因子或相对于S.Mansoni的幼虫幼虫能够抑制IgE依赖性血小板citotoxicity的抗原，强烈地减少反应IgE中血小板的化学发光 -anti-IgE，其是抗寄生虫细胞毒性的相关性，并且在非IgE依赖性遗传中抑制血小板活化。 用作抑制血小板活化的抑制剂和作为过敏的免疫调节剂药物。
-
9.发明申请Device for the Presentation of Peptides or Proteins, Method for the Preparation and Use Thereof 审中-公开用于表达肽或蛋白质的装置，其制备和使用方法公开(公告)号：US20070243623A1
公开(公告)日：2007-10-18
申请号：US10515190
申请日：2003-05-15
申请人： Oleg Melnyk , Xavier Duburcq , Helene Gras-Masse , Christophe Olivier , Fengling Zhou , Claude Auriault , Ahmed Bouzidi
发明人： Oleg Melnyk , Xavier Duburcq , Helene Gras-Masse , Christophe Olivier , Fengling Zhou , Claude Auriault , Ahmed Bouzidi
CPC分类号： C07K17/14 , C07K1/1077 , Y10T436/25
摘要： The invention relates to a device for the presentation of polypeptides, a method for the preparation and the use thereof, as diagnostic tool (polypeptide chip) for miniaturized and highly parallel detection of structurally or functionally complementary molecules of said polypeptides, i.e. antibodies.
摘要翻译： 本发明涉及用于呈现多肽的装置，其制备方法和用途，作为用于微型化和高度平行检测所述多肽（即抗体）的结构或功能互补分子的诊断工具（多肽芯片）。
-
公开(公告)号：US06818219B1
公开(公告)日：2004-11-16
申请号：US09446907
申请日：2000-04-10
申请人： Denis Tranchand-Bunel , Hélène Gras-Masse , Claude Auriault , André Tartar , Eric Diesis , Brigitte Bourez
发明人： Denis Tranchand-Bunel , Hélène Gras-Masse , Claude Auriault , André Tartar , Eric Diesis , Brigitte Bourez
IPC分类号： A61K3912
CPC分类号： G01N33/56994 , C07K14/005 , C12N2710/16222 , C12N2710/16622 , G01N2333/05
摘要： The invention concerns a reagent for diagnosing an infection caused by a virus, characterized in that it comprises essentially a mixture consisting of (1) an immunodominant fragment of a protein of said virus comprising not more than 60 aminoacids, preferably between 20 and 30 aminoacids and (2) a mixture (called mixotope) of convergent combining peptides, derived from said immunodominant fragment, which peptides are obtained by total or partial artificial degeneration of said immunodominant fragment by systematic or partial replacement of each aminoacid by another according to an appropriate substitution matrix. The invention concerns a reagent for detecting and monitoring infections caused by the Epstein-Barr virus of EBV, which is, in particular, the causal agent of infectious mononucleose and its applications for detecting an EBV infection at any stage of the infection (primo-infection, healthy carriers and induced tumors). Said diagnosis reagent comprises essentially a mixture consisting of (1) a C-terminal fragment of the protein VCAp18 SEQ ID no 1 of the Epstein-Barr virus (EBV) comprising not more than 60 aminoacids, preferably between 20 and 30 aminoacids, and (2) a mixture of convergent combining peptides, derived from said C-terminal fragment.
摘要翻译： 本发明涉及用于诊断由病毒引起的感染的试剂，其特征在于其基本上由以下组成的混合物组成：（1）所述病毒的蛋白质的免疫显性片段，其包含不超过60个氨基酸，优选20-30个氨基酸，以及 （2）衍生自所述免疫显性片段的会聚结合肽的混合物（称为mixotope），所述肽通过所述免疫显性片段的全部或部分人工变性通过根据适当的取代基团对另一个氨基酸进行系统或部分置换而获得 。 本发明涉及用于检测和监测由EBV的爱泼斯坦 - 巴尔病毒引起的感染的试剂，其特别是感染性单核细胞的致病因子及其在感染的任何阶段检测EBV感染的应用（初始感染 ，健康载体和诱导的肿瘤）。 所述诊断试剂基本上由以下组成的混合物组成：（1）包含不超过60个氨基酸，优选20-30个氨基酸的爱泼斯坦 - 巴尔病毒（EBV）的蛋白质VCAp18 SEQ ID n1的C末端片段 ，和（2）衍生自所述C-末端片段的会聚结合肽的混合物。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)
